FY2025 EPS Estimates for XOMA Royalty Reduced by Analyst

XOMA Royalty Corporation (NASDAQ:XOMA) – Analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for XOMA Royalty in a research report issued on Thursday, December 11th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will earn $0.51 per share for the year, down from their previous estimate of $1.17. HC Wainwright has a “Buy” rating and a $97.00 price target on the stock. The consensus estimate for XOMA Royalty’s current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for XOMA Royalty’s Q4 2025 earnings at $0.05 EPS and FY2026 earnings at $0.61 EPS.

Other analysts have also recently issued reports about the stock. Leerink Partners cut their price target on shares of XOMA Royalty from $58.00 to $45.00 and set an “outperform” rating on the stock in a report on Thursday. Zacks Research downgraded shares of XOMA Royalty from a “hold” rating to a “strong sell” rating in a research report on Tuesday, November 18th. Stifel Nicolaus set a $50.00 price objective on shares of XOMA Royalty in a research note on Friday. UBS Group set a $76.00 target price on XOMA Royalty in a report on Tuesday, December 9th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of XOMA Royalty in a report on Monday, December 8th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $60.60.

XOMA Royalty Stock Down 5.0%

Shares of XOMA Royalty stock opened at $25.22 on Monday. The business has a 50-day moving average of $33.31 and a 200-day moving average of $31.06. XOMA Royalty has a 1-year low of $18.35 and a 1-year high of $39.92. The company has a market capitalization of $312.22 million, a PE ratio of 34.08 and a beta of 0.94. The company has a debt-to-equity ratio of 1.07, a current ratio of 3.91 and a quick ratio of 3.91.

XOMA Royalty (NASDAQ:XOMA) last announced its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.33). The firm had revenue of $9.35 million during the quarter, compared to analysts’ expectations of $11.47 million. XOMA Royalty had a net margin of 32.28% and a return on equity of 2.91%.

Institutional Trading of XOMA Royalty

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in XOMA Royalty by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 668,111 shares of the biotechnology company’s stock valued at $25,749,000 after buying an additional 29,298 shares during the last quarter. Opaleye Management Inc. boosted its holdings in XOMA Royalty by 0.8% during the second quarter. Opaleye Management Inc. now owns 255,087 shares of the biotechnology company’s stock valued at $6,428,000 after acquiring an additional 2,044 shares during the period. Woodline Partners LP boosted its holdings in XOMA Royalty by 16.5% during the third quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company’s stock valued at $8,091,000 after acquiring an additional 29,715 shares during the period. Geode Capital Management LLC grew its position in shares of XOMA Royalty by 9.1% in the second quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company’s stock valued at $5,132,000 after purchasing an additional 16,929 shares during the last quarter. Finally, Stonepine Capital Management LLC increased its stake in shares of XOMA Royalty by 17.2% in the second quarter. Stonepine Capital Management LLC now owns 152,143 shares of the biotechnology company’s stock worth $3,834,000 after purchasing an additional 22,330 shares during the period. 95.92% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at XOMA Royalty

In other XOMA Royalty news, CEO Owen Hughes bought 100,000 shares of the firm’s stock in a transaction on Thursday, December 4th. The stock was bought at an average cost of $25.05 per share, with a total value of $2,505,000.00. Following the completion of the transaction, the chief executive officer directly owned 102,000 shares of the company’s stock, valued at approximately $2,555,100. The trade was a 5,000.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Thomas M. Burns sold 4,330 shares of the stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $35.99, for a total transaction of $155,836.70. Following the transaction, the chief financial officer owned 30,079 shares in the company, valued at approximately $1,082,543.21. This trade represents a 12.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 7.20% of the company’s stock.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.